NASDAQ:CLDX Celldex Therapeutics (CLDX) Stock Price, News & Analysis $44.56 +0.70 (+1.60%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$43.11▼$46.8350-Day Range$32.76▼$44.5652-Week Range$22.11▼$53.18Volume1.05 million shsAverage Volume659,913 shsMarket Capitalization$2.94 billionP/E RatioN/ADividend YieldN/APrice Target$62.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Celldex Therapeutics alerts: Email Address Celldex Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside39.5% Upside$62.17 Price TargetShort InterestBearish11.21% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.94Based on 5 Articles This WeekInsider TradingSelling Shares$9.16 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.39) to ($2.85) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.86 out of 5 starsMedical Sector846th out of 936 stocksDiagnostic Substances Industry12th out of 15 stocks 3.4 Analyst's Opinion Consensus RatingCelldex Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCelldex Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Celldex Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted11.21% of the outstanding shares of Celldex Therapeutics have been sold short.Short Interest Ratio / Days to CoverCelldex Therapeutics has a short interest ratio ("days to cover") of 11.5, which indicates bearish sentiment.Change versus previous monthShort interest in Celldex Therapeutics has recently increased by 5.72%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCelldex Therapeutics does not currently pay a dividend.Dividend GrowthCelldex Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CLDX. Previous Next 2.7 News and Social Media Coverage News SentimentCelldex Therapeutics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Celldex Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for CLDX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Celldex Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Celldex Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,155,821.00 in company stock.Percentage Held by InsidersOnly 3.80% of the stock of Celldex Therapeutics is held by insiders.Read more about Celldex Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Celldex Therapeutics are expected to decrease in the coming year, from ($2.39) to ($2.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Celldex Therapeutics is -15.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Celldex Therapeutics is -15.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCelldex Therapeutics has a P/B Ratio of 4.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Celldex Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."Click here now to watch this exclusive interview About Celldex Therapeutics Stock (NASDAQ:CLDX)Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.Read More CLDX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CLDX Stock News HeadlinesJuly 23, 2024 | markets.businessinsider.comCelldex Stock Fairly Valued Amid Competition and Market Anticipation: Hold Rating MaintainedJuly 17, 2024 | americanbankingnews.comCelldex Therapeutics' (CLDX) Buy Rating Reiterated at HC WainwrightJuly 27, 2024 | Stansberry Research (Ad)Get out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."July 16, 2024 | globenewswire.comCelldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous UrticariaJune 4, 2024 | globenewswire.comCelldex Therapeutics to Present at Jefferies Healthcare ConferenceJune 2, 2024 | globenewswire.comCelldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024May 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Celldex on Promising Barzolvolimab Trials in Inflammatory DiseasesMay 15, 2024 | globenewswire.comCelldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo NodularisJuly 27, 2024 | Stansberry Research (Ad)Get out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."May 10, 2024 | seekingalpha.comCelldex Therapeutics: Rising High, With Room For Further GrowthMay 8, 2024 | finance.yahoo.comCelldex Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagMay 7, 2024 | finanznachrichten.deCelldex Therapeutics, Inc.: Celldex Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 7, 2024 | markets.businessinsider.comUnveiling 4 Analyst Insights On Celldex TherapeuticsMay 6, 2024 | investorplace.comCLDX Stock Earnings: Celldex Therapeutics Beats EPS, Misses Revenue for Q1 2024May 6, 2024 | globenewswire.comCelldex Reports First Quarter 2024 Financial Results and Provides Corporate UpdateApril 19, 2024 | investing.comCelldex completes patient enrollment for Phase 2 urticaria trialApril 17, 2024 | msn.comCelldex Hails Enrolment News, Shares Poke AheadApril 17, 2024 | finance.yahoo.comCelldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible UrticariaSee More Headlines Receive CLDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Celldex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/06/2024Today7/27/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryBiotechnology Current SymbolNASDAQ:CLDX CUSIP15117B10 CIK744218 Webwww.celldex.com Phone(908) 454-7120Fax908-454-1911Employees150Year Founded1983Price Target and Rating Average Stock Price Target$62.17 High Stock Price Target$90.00 Low Stock Price Target$27.00 Potential Upside/Downside+39.5%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.85) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-141,430,000.00 Net Margins-2,385.57% Pretax Margin-2,385.57% Return on Equity-29.55% Return on Assets-27.66% Debt Debt-to-Equity RatioN/A Current Ratio31.77 Quick Ratio31.77 Sales & Book Value Annual Sales$6.88 million Price / Sales426.88 Cash FlowN/A Price / Cash FlowN/A Book Value$9.08 per share Price / Book4.91Miscellaneous Outstanding Shares65,910,000Free Float63,406,000Market Cap$2.94 billion OptionableOptionable Beta1.58 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Anthony S. Marucci M.B.A. (Age 62)Founder, President, CEO & Director Comp: $1.27MDr. Tibor Keler Ph.D. (Age 65)Founder, Chief Scientific Officer & Executive VP Comp: $810.39kMr. Sam Martin (Age 53)Senior VP, CFO, Secretary & Treasurer Comp: $676.87kDr. Margo Heath-Chiozzi M.D. (Age 67)Senior Vice President of Regulatory Affairs Comp: $667.21kDr. Diane C. Young M.D. (Age 67)Senior VP & Chief Medical Officer Comp: $696.45kProf. Joseph P. Schlessinger Ph.D. (Age 79)Co-Founder & Member of Scientific Advisory Board Ms. Sarah Cavanaugh (Age 49)Senior Vice President of Corporate Affairs & Administration Mr. Freddy A. Jimenez Esq. (Age 55)Senior VP & General Counsel Comp: $579.7kDr. Ronald A. Pepin (Age 68)Chief Business Officer & Senior VP Comp: $441.84kMs. Elizabeth Crowley (Age 52)Chief Product Development Officer & Senior VP Comp: $507.24kMore ExecutivesKey CompetitorsRiot PlatformsNASDAQ:RIOTIntellia TherapeuticsNASDAQ:NTLANeogenNASDAQ:NEOGMeridian BioscienceNASDAQ:VIVOHeskaNASDAQ:HSKAView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 29,324 shares on 7/26/2024Ownership: 0.349%AlphaCentric Advisors LLCBought 9,000 shares on 7/26/2024Ownership: 0.072%Overbrook Management CorpSold 252 shares on 7/25/2024Ownership: 0.010%Values First Advisors Inc.Bought 1,627 shares on 7/19/2024Ownership: 0.032%Assenagon Asset Management S.A.Bought 48,231 shares on 7/18/2024Ownership: 0.211%View All Insider TransactionsView All Institutional Transactions CLDX Stock Analysis - Frequently Asked Questions How have CLDX shares performed this year? Celldex Therapeutics' stock was trading at $39.66 on January 1st, 2024. Since then, CLDX stock has increased by 12.4% and is now trading at $44.56. View the best growth stocks for 2024 here. How were Celldex Therapeutics' earnings last quarter? Celldex Therapeutics, Inc. (NASDAQ:CLDX) issued its earnings results on Monday, May, 6th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, beating analysts' consensus estimates of ($0.67) by $0.11. The biopharmaceutical company earned $0.16 million during the quarter, compared to analyst estimates of $1.30 million. Celldex Therapeutics had a negative trailing twelve-month return on equity of 29.55% and a negative net margin of 2,385.57%. When did Celldex Therapeutics' stock split? Shares of Celldex Therapeutics reverse split on Monday, February 11th 2019. The 1-15 reverse split was announced on Friday, February 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 8th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are Celldex Therapeutics' major shareholders? Celldex Therapeutics' top institutional shareholders include Bank of New York Mellon Corp (0.35%), Assenagon Asset Management S.A. (0.21%), Mirador Capital Partners LP (0.17%) and AlphaCentric Advisors LLC (0.07%). Insiders that own company stock include Samuel Bates Martin, Richard M Wright, Elizabeth Crowley, Margo Heath-Chiozzi, Diane C Young, Sarah Cavanaugh and Freddy A Jimenez. View institutional ownership trends. How do I buy shares of Celldex Therapeutics? Shares of CLDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Celldex Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Celldex Therapeutics investors own include OPKO Health (OPK), Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Corbus Pharmaceuticals (CRBP), Precigen (PGEN), Micron Technology (MU) and Dynavax Technologies (DVAX). This page (NASDAQ:CLDX) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored4 Steps to Survive the Coming Market CrashCracks threaten us with a widespread collapse unlike anything we've seen in our lifetime. During this prese...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celldex Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celldex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CLDX Stock Alerts